Unknown

Dataset Information

0

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.


ABSTRACT: BACKGROUND:Tissue released blood-based biomarkers can provide insight into drug mode of action and response. To understand the changes in extracellular matrix turnover, we analyzed biomarkers associated with joint tissue turnover from a phase 3, randomized, placebo-controlled study of baricitinib in patients with active rheumatoid arthritis (RA). METHODS:Serum biomarkers associated with synovial inflammation (C1M, C3M, and C4M), cartilage degradation (C2M), bone resorption (CTX-I), and bone formation (osteocalcin) were analyzed at baseline, and weeks 4 and 12, from a subgroup of patients (n =?240) randomized to placebo or 2-mg or 4-mg baricitinib (RA-BUILD, NCT01721057). Mixed-model repeated measure was used to identify biomarkers altered by baricitinib. The relationship between changes in biomarkers and clinical measures was evaluated using correlation analysis. RESULTS:Treatment arms were well balanced for baseline biomarkers, demographics, and disease activity. At week 4, baricitinib 4-mg significantly reduced C1M from baseline by 21% compared to placebo (p 

SUBMITTER: Thudium CS 

PROVIDER: S-EPMC7552555 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.

Thudium Christian S CS   Bay-Jensen Anne C AC   Cahya Suntara S   Dow Ernst R ER   Karsdal Morten A MA   Koch Alisa E AE   Zhang Wenling W   Benschop Robert J RJ  

Arthritis research & therapy 20201012 1


<h4>Background</h4>Tissue released blood-based biomarkers can provide insight into drug mode of action and response. To understand the changes in extracellular matrix turnover, we analyzed biomarkers associated with joint tissue turnover from a phase 3, randomized, placebo-controlled study of baricitinib in patients with active rheumatoid arthritis (RA).<h4>Methods</h4>Serum biomarkers associated with synovial inflammation (C1M, C3M, and C4M), cartilage degradation (C2M), bone resorption (CTX-I)  ...[more]

Similar Datasets

| S-EPMC8217482 | biostudies-literature
| S-EPMC6560251 | biostudies-literature
| S-EPMC5517434 | biostudies-literature
2023-05-24 | GSE221704 | GEO
| S-EPMC6676493 | biostudies-literature
| S-EPMC8302689 | biostudies-literature
| S-EPMC7784289 | biostudies-literature
| S-EPMC8121442 | biostudies-literature
2016-03-16 | GSE74143 | GEO
| S-EPMC8250677 | biostudies-literature